Abstract Patients with mitochondrial ornithine transporter deficiency (or HHH syndrome) present with various neurological symptoms, including mental retardation, spastic paraparesis with pyramidal signs, cerebellar ataxia, and episodic disturbance of consciousness or coma due to hyperammonemia. We previously described three novel mutations in the ORNT1 gene in Japanese patients with HHH syndrome. In this article, we report a new patient with HHH syndrome, a 52-year-old woman, who had the typical clinical features, except for an absence of mental retardation. When we screened this patient, as well as a previously described Japanese patient, for mutations in the ORNT1 gene, we found that both were homozygous for a nonsense mutation (R179X). Furthermore, reverse transcription (RT)-polymerase chain reaction (PCR) of fibroblast RNA from one patient showed exon 4 skipping, as had been observed in a previously reported patient with R179X. These results, together with the findings in our previous report, show that, in three of our five reported Japanese HHH patients (six of ten alleles), R179X is present, suggesting that this is a common mutation in Japanese patients with HHH syndrome.
Introduction
Mitochondrial ornithine transporter deficiency, or HHH syndrome (MIM 238970) is characterized by three biochemical abnormalities; hyperornithinemia, hyperammonemia, and homocitrullinuria (Camacho et al. 1999) . Clinically, HHH syndrome presents with mental retardation, seizures, spastic paraparesis with pyramidal signs, cerebellar ataxia, and episodic disturbance of consciousness or coma due to hyperammonemia (Valle and Simell 1995) . More than 50 patients have been reported since Shih et al. first reported this syndrome in 1969. We previously reported three novel mutations in the ORNT1 gene in Japanese patients with HHH syndrome (Tsujino et al. 2000) .
In this article, we report a new patient, as well as the results of screening this patient and a previously reported Japanese patient for the three mutations reported by Tsujino et al. (2000) , using polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP) analysis and the amplification refractory mutation system (ARMS) method.
Patients and methods

Patient 1
Patient 1, a 52-year-old woman, had spastic gait and cerebellar signs such as dysmetria, dysdiadochokinesis, and scanning speech, since adolescence. There was no information about consanguinity. She had had spastic paraparesis and paroxysmal involvement of the upper extremities since the age of 27 years. At the age of 36 years, hyperammonemia was noted, and a protein-restricted diet and kanamycin were prescribed. At age 37, she complained of tension in her legs and had surgery to elongate the Achilles tendons in both legs. When she was diagnosed with HHH syndrome at age 52, the ornithine concentration in serum was elevated, at 373 nmol/µl (normal range, 36-110 nmol/ µl), and homocitrullinuria was shown. Her blood ammonia level after meals was increased, at 126-404 µg/dl (normal range, less than 80 µg/dl).
Patient 2
Patient 2 was previously described elsewhere (Nakajima et al. 1988) . Briefly, He was a 10-year-old boy, with healthy Japanese parents who are first cousins. He was delivered at 38 weeks gestation, with a birth weight of 1850 g. His developmental milestones were delayed in late infancy. At the age of 3 years, spastic paraplegia was noted. He always avoided the intake of meat, milk, and eggs. At the age of 10, he had an episode of lethargy and hyperammonemia. Neurological examination showed spastic diplegia, hyperkinetic behavior, severe mental retardation, and truncal ataxia. On examination, his fasting blood ammonia level was found to be 185-340 µg/dl (normal range, less than 80 µg/dl), serum ornithine ranged between 185 and 514 µg/dl (normal range, 50-80 µg/dl), and a large amount of homocitrulline was excreted in the urine.
PCR amplification of genomic DNA and sequencing Genomic DNA was isolated from peripheral leukocytes or cultured skin fibroblasts of the two patients and a normal control. Intronic primers 1 (5Ј-tccttactagtgcttgatcag-3Ј) and 2 (5Ј-ctgcttcaggccctgtcctaa-3Ј) amplified a DNA fragment containing exon 4 by PCR as described (Tsujino et al. 2000) . For sequencing, the PCR products were purified with a GeneElute Agarose Spin Column (Sigma, St Louis, MO, USA) or with a QIAquick PCR purification Kit (Qiagen, Hilden, Germany); direct sequencing was done with the Dye Terminator Cycle Sequencing FS Ready Reaction Kit (PE Biosystems, Foster City, CA, USA) with primers 1 and 2 and an ABI Prism 310 Genetic Analyzer (PE Biosystems), according to the manufacturer's instructions.
PCR-based detection of the three mutations
A PCR fragment with primers 1 and 2 was digested with Taq α I (New England Biolabs, Beverly, MA, USA). In the presence of the nonsense mutation (R179X), the PCR product was not cleaved by the restriction endonuclease Taq α I, whereas the wild-type PCR product was cleaved (Fig. 1A) . Restriction digests were analyzed in 2% NuSieve (Rockland, ME, USA) agarose. Detection of the two other mutations (G27E or 228/229 ins AAC) was performed with PCR-RFLP or ARMS as described (Tsujino et al. 2000) .
Results and discussion
Digestion of the PCR fragment containing exon 4 with Taq α I revealed that both patients were homozygous for a C-to-T transition, resulting in a change of CGA to TGA at codon 179 (R179X) (Fig. 1B) . This was confirmed by sequencing the PCR products. Neither patient had either of the other two mutations (G27E or 228/229 ins AAC). We also detected exon 4 skipping in the reverse transcription (RT)-PCR product of patient 2, similar to what we had found previously in another patient with R179X (Tsujino et al. 2000) . Camacho et al. (1999) reported two mutations and a microdeletion in 11 patients with HHH syndrome (Table 1) . One patient was a genetic compound heterozygote. He had the E180K mutation on one allele, which he inherited from his father, who was Irish-American and was heterozygous for E180K. On the other allele, he carried a microdeletion involving ORNT1, which he inherited from his mother, who was Japanese. She did not have the E180K mutation, but was heterozygous for the microdeletion. The other 10 patients were all French-Canadian, 9 of whom were homozygous for the F188 deletion. The remaining patient was a compound heterozygote for the F188 deletion and an as yet unknown mutation. Shih and Ficicioglu (2000) also reported mutations in 11 patients with HHH syndrome. An A15E mutation was identified in a Palestinian infant and a CA insertion following the 96th nucleotide in a South American girl. The other 9 patients were French-Canadian, 7 of whom were homozygous and 2 of whom were heterozy- gous for the F188 deletion (the second allele in these 2 patients was not identified).
The results in the present study, together with the findings in our previous report, show that, in three of our five reported Japanese HHH patients (six of ten alleles), R179X is present, suggesting that this is a common mutation in Japanese patients with HHH syndrome. The home towns of the three Japanese patients with R179X were Nima-gun (Shimane prefecture), Onomichi (Hiroshima prefecture), and Numazu (Shizuoka prefecture). While the towns of Nima-gun and Onomichi are comparatively close to each other, Numazu is far from these two towns. This suggests that the R179X allele may be widely distributed in Japan. Although it is believed that HHH syndrome is a relatively rare disorder, there may be additional Japanese patients who remain undiagnosed. We conclude that screening for R179X may be useful for the diagnosis of HHH syndrome in Japanese patients.
